Beyond Air Schedules Second Fiscal Quarter 2023 Financial Results Conference Call and Webcast

Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that it will report financial results for its second fiscal quarter ended September 30, 2022 on Tuesday, November 8, 2022. The Company’s management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the same day.